Latest News

Mavenclad® Cladribine – Have your Say by Friday 22nd September 2023

September 19, 2023 | Treatments

Mavenclad® Cladribine – Have your Say MSNZ is currently preparing a submission to Pharmac to urge them to again consider funding Mavenclad (Cladribine) for Relapsing Remitting MS. Our submission is due this Friday 22nd September. Real world and clinical trial […]


Ocrevus for PPMS – Your Questions Answered

September 14, 2023 | Treatments

  Here’s what you need to know about Ocrevus (ocrelizumab) for Primary Progressive MS. Download PDF copy here.   What medicines are available to treat Primary Progressive Multiple Sclerosis (PPMS)?  There is only one medicine, Ocrevus® (ocrelizumab), that has been […]


Media Release: “Relief” over Pharmac Decision to Fund First-Ever Treatment for Debilitating Form of Multiple Sclerosis

September 4, 2023 | Advocacy, Media, Progressive, Treatments

A seven year battle on behalf of hundreds of people living with the most debilitating form of Multiple Sclerosis has been won – with Pharmac agreeing to fund Aotearoa New Zealand’s first ever treatment for the disease variant  from October […]


World Health Organisation adds three Disease Modifying Therapies for MS onto Essential Medicine List

July 27, 2023 | Treatments

Image: myriam-zilles-unsplash Today, the World Health Organisation (WHO) added three Disease Modifying Treatments (DMTs) for Multiple Sclerosis (MS) onto its Essential Medicines List for the first time. Addressing the global MS movement, Prof Mai Sharawy, Chair of the Board of […]


aHSCT for MS in New Zealand – Webinar Recording Now Available

June 1, 2023 | Treatments, Webinar

Multiple Sclerosis New Zealand (MSNZ) and the New Zealand Multiple Sclerosis Research Trust (NZMSRT) are pleased to share with you our aHSCT for MS in New Zealand webinar that marked World MS Day on 30 May. Autologous haematopoetic stem cell […]